Biotech Syllabus

8/13/2019 Biotech Syllabus

1/4

Code 205: Plant Biotechnology

Unit 1: Introduction of plant tissue culture and cell suspension culture, physico-chemical conditions for

propagation of plant cells and tissues, composition of media, nutrient and hormone requirement,

continuous culture, techniques for immobilization of plant cells, continuous product recovery system

using immobilized plant cell system.

Unit 2: Plant tissue culture product and recovery:

Primary and secondary metabolic products (phytochemicals) of plant cells, biosynthesis of

secondary metabolites of Biotechnological importance, biotransormation for product development

and selection of cell culture, process technology ith salient features for specific products.

Unit !: Plant tissue culture genetic engineering !a": #tructure and organisation of plant genome,

regulation of plant genome e$pression, transcriptional, translational and post

transcriptional regulation of plant genome. - %ransposons, chloroplast and mitochondrial genome.

Unit ": Plant tissue culture genetic engineering !b": %ransfer of nucleic acid to plant cells

- &irect transformation by electroporation and particle gun bombardment. 'grobacterium, %i plasmid

vector %heory and techniques for the development of ne genetic traits, conferring resistance to

herbicide, pesticide, plant pathogens.

Unit 5: Plant engineering toards development of enriched food products, plant groth regulators,

(olecular pharming.

Unit #: Introduction to primary and secondary metabolites, important pathay leading to the

biosynthesis of secondary metabolites !e.g. serpentine, shin)onin, diosgenin and cardenolids" in plants,

Unit $: (etabolic products produced by in vitro culturing of plant cells, selection of plant cells*tissues

for the production of a specific product, +ulture system in secondary plant product biosynthesis-batch

continuous cultures and immobilized plant cells, biotransformation of precursors by cell culturing.

Unit %: $traction and analytical methods for the above four metabolites. Industries involved in the

production of plant secondary metabolites, Potential and future prospect of the secondary metabolites

production by plant cell culture techniques.


2/4

&e't Boos:

. +ripeels, (.. and #adava, &.., Plants, /enes and Biotechnology, 0ones and Biotechnology,

ones and Bartlett Publishers ,1*e, 1223

1. Bho0ani, #.#., Plant %issue +ulture: 'pplication and 4imitations. 'msterdam, lsevier,552.

3. +hartes, +unningham and 'ndre .6. Porter, 6ecombinant Proteins from 7lans Production and

Isolation of +linically 8seful +ompounds ,9umana Press,55

;. Bemard 6./lic) and ohn . %hompson, (ethods in Plant (olecular Biology and

Biotechnology, +6+ Press, 553.


3/4

lecti*e +

C-. 20#: /U&-/3 44+/ 6. C+6+C &/+

U6+& 71: +6&/-.UC&+-6 &- C+6+C &/+:a brief history of clinical trials-- types of

clinical trials-- ethics of clinical trials-- +linical %rial Protocols

U6+& 72: .+6 6. -/6+&+-6 -4 C+6+C &/+: treatment assignment

methods: simple randomisation, bloc)ed randomisation, stratified randomisation ---minimisation

method- unequal randomisation - the size of a clinical trial-reporting results- 6oles and responsibilities

of clinical research personnel according to I+9-/+PU6+& 7! : 8-6+&-/+6 &/+ P/-/: +6&/-.UC&+-67 -U&C-8 8U/-

compliance, &ropouts and-Intention-%o-%reat- ' %a$onomy 7f &ropouts- Interim 'nalyses In +linical

%rials- /roup #equential Procedures--- ' Bayesian Perspective. 'udits in +linical 6esearch

U6+& 7": B+C 63 -4 C+6+C &/+: Introduction- Brief 6evie #tatistics-

enerali9ed inear models: 8odels or Counts: &reatment o 4amilial denomatous Polyposis

(4P) ith a 6on7teroidal nti7+nlammatory .rug 7-rdinal /esponse 8odels: Clinical &rial

in ymphoma 7 8odels ith parallel 7 6on7parallel models 7 8odel estimation linear predictors7

multiple endpoints- 'nalysis of 4ongitudinal &ata from +linical %rials

U6+& 75: ;+&-/3 -4 /U&-/3 44+/, (ain concepts A#- 6egulatory affairs for

studies in human sub0ects- data needed-4icensing authorities-roles and responsibilities,I+9 -/+P,&',8 +linical %rial- 6egulatory submissions and 6equirements for gaining approval of ne products-

6egulating control over mar)eting and sales of medical products

U6+& 7#: &ocumentation and (aintenance of records.

U6+& 7$: &rug C +osmetics 'ct ith special reference to schedule ? and ( , schedule of medical

devices. +oncept of total quality management, requirements of /(P, /4P, /+P, 6egulatoryrequirements of drugs and Pharmaceutical !8#&-@&'* '@&'"


4/4

U6+& 7%: +6&C&U P/-P/&3 /+;&patents, %rademar)s, +opyrights, Patents 'ct.

&

Documents

Biotech Syllabus